Tuberculosis (TB) remains an important public health problem, particularly among people infected with the human immunodeficiency virus (HIV).

An international research team led by scientists from Vanderbilt University Medical Center has identified a genetic variant that protects people with HIV from developing active tuberculosis. The variant is near the gene encoding the infection-fighting cytokine IL-12.

One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered.

Routine tuberculosis (TB) skin testing for Vanderbilt staff and faculty will resume Monday, Dec. 16, after temporarily being suspended since September due to a national shortage of the TB skin testing solution Tubersol.

Clinicians should be cautious about prescribing newer fluoroquinolone antibiotics to patients with TB risk factors; doing so may jeopardize the use of these agents against TB.

Due to a national shortage of the tuberculosis (TB) test solution Tubersol, Occupational Health will temporarily suspend routine annual skin tests, effective Sept. 1, said Patricia Kinman, MSN, FNP-BC, manager of the Vanderbilt Occupational Health Clinic

Vanderbilt University investigators have developed a new strategy for identifying the “bits” of a pathogen that spark a protective immune response.